Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Association of a Novel Index of Early-life Growth Conditions With Chronic Obstructive Pulmonary Disease Phenotype and Prognosis
Alter, M J, Debban, Catherine L., Goldman-Pham, R. , Bleecker, Eugene R. , Christenson, Stephanie A. , Cooper, C.B., Martinez, F.J., Meyers, D.A., Ortega, Victor E. , Paine, Robert , Rennard, S.I., Woodruff, P., Investigators, for the Watch the Spot, Christenson, Stephanie A , Alter, M., Barr, R. Graham , Barjaktarević, Igor , Cooper, C.B. , Couper, David , Lovinsky‐Desir, Stephanie , Han, Mingyuan , Martinez, F.J., Meyers, D.A., Rennard, S.I., Manichaikul, Ani , Smith, Benjamin M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5005-A5005

10.1164/ajrccm.2025.211.abstracts.a5005 Get It

Abstract Rationale Chronic obstructive pulmonary disease (COPD) manifests later in life and is a leading cause of death worldwide. While smoking-related lung pathology is a long-recognized COPD etiotype, emerging evidence suggests that early-life growth conditions also play an important role. A recently-developed index of early-life growth conditions – the difference between attained height and genotype-predicted height (height-GaP) – has been validated against prospectevely ascertained adverse early-life growth conditions. This study used height-GaP to evaluate the association of early-life growth conditions with COPD phenotype and prognosis later in life. Methods Among current and former smokers with spirometry-defined COPD in the SubPopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS), we computed height-GaP as the difference between attained height and genotype-predicted height. Regression models were fit for respiratory mortality (defined by primary diagnostic code), dyspnea prevalence (Medical Research Council dyspnea rating >1), chronic bronchitis prevalence, airflow obstruction severity as quantified by FEV1Q, and functional capacity (six-minute walk distance), adjusting for age, age2, sex, race-ethnicity, genotype-predicted height, cigarette smoking status and pack-years. Sensitivity analyses accounted for competing risks of death (Fine-Gray subdistribution hazard model) and accounted for later-life height loss (restricting sample to participants under 50 years). Results Among 1,258 participants with COPD (mean±SD age: 65.4±8.0 years, 42.4% female, mean±SD pack-years: 53.6±28.2, mean±SD FEV1%: 63.3±23.9%), there were 202 respiratory deaths over a median 7.5 years of follow-up (Figure). Larger height-GaP deficit was associated with higher respiratory mortality (adjusted hazard ratio [aHR]: 1.30 [95%CI: 1.12 to 1.50] per 1-SD increment in height-GaP deficit). This association remained significant after accounting for competing events (p=0.001) and when restricted to participants under 50 years (p=0.032). Larger height-GaP deficit was associated with higher dyspnea prevalence (adjusted prevalence ratio: 1.13 [95%CI: 1.02 to 1.25] per 1-SD increment in height-GaP deficit), lower FEV1Q (adjusted mean difference: -0.37 [95%CI: -0.45 to -0.29] per 1-SD height-GaP deficit), and shorter 6-minute walk (adjusted mean difference: -16.6 m [95%CI: -23.1 m to -10.0 m] per 1-SD increment in height-GaP deficit), but not chronic bronchitis or CAT score ≥10 (p>0.05 for each). Conclusions Among current and former smokers with COPD, a quantitative index of early-life conditions was associated with higher respiratory mortality, in addition to dyspnea, airflow obstruction severity and reduced functional capacity. These results suggest that early-life growth conditions may influence COPD phenotype and prognosis later in life.
Releasing the Brakes in IPF: Inflammatory Fibroblasts Alter the Alveolar Niche to Promote Epithelial Expansion
Barboza, W.J. Roque, Murthy, A., Bui, Sarah, Tomer, Yaniv , Cooper, Cathleen, Chroneos, Rea, Reineberg, Anamarie, Tschumperlin, Daniel J. , Beers, Michael F. , Rodríguez, L. Raposo , Espinosa, Ana M. Diaz , Cooper, C.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4998-A4998

10.1164/ajrccm.2025.211.abstracts.a4998 Get It

Abstract Rationale: Application of single cell RNAseq (scRNAseq) in idiopathic pulmonary fibrosis (IPF) and multiple murine models has revealed two unique disease associated fibroblast subsets, the Cthrc1+ fibrotic population, and a population expressing inflammatory markers whose function is unclear. We, and others, have demonstrated that inflammatory fibroblasts are derived from homeostatic fibroblasts and can differentiate to Cthrc1+ fibroblasts. There is also data in mice suggesting that TGFβ inhibition prevents the emergence of Cthrc1+ fibrotic fibroblasts without impacting the inflammatory fibroblast population. Using our inducible genetic murine model of PF, reductionist organoid systems, and scRNAseq from IPF we present evidence and mechanism for inflammatory fibroblasts as a potential regenerative population in the alveolar niche. Methods: Tamoxifen administration to SftpcI73T conditional allelic knock-in mice, induces expression of mutant protein and promotes an inflammatory cascade followed by fibrogenesis. ScRNA-seq and population RNA-seq of bleomycin and SftpcI73T murine models were compared with publicly available data sets from IPF to identify population specific surface marker expression and potential epithelial ligand-receptor pairs. Flow cytometry approaches developed to isolate fibroblast populations were applied for in-vitro organoid modeling and validation of signaling pathways. In-vivo murine intervention in TGFβ signaling was further applied to confirm functional biology of inflammatory fibroblasts. Results: Informatic analysis of human and mouse inflammatory fibroblasts identifies expression of multiple BMP antagonists that have previously been associated with epithelial proliferation. Furthermore, human inflammatory fibroblasts also express key epithelial growth factors including FGF2 and FGF7. Murine organoid modeling confirms that inflammatory fibroblasts support alveolar organoid formation through the inhibition of BMP signaling. As was previously demonstrated in bleomycin, the inhibition of TGFβ signaling in SftpcI73T does not alter the inflammatory fibroblast population, rather this population is sustained, and alveolar epithelial proliferation increases. Additionally, we did not find any evidence for increase inflammation in the mouse lung due to inflammatory fibroblasts preservation. Finally, human data suggests that two populations of inflammatory fibroblasts are present in the lung with only one subset found to express the BMP antagonists and growth factors required to promote alveolar epithelial proliferation. Conclusions: Our data identifies that inflammatory fibroblasts in the alveolar niche inhibit BMP signaling and allow for epithelial expansion. We also determine differences between murine and human inflammatory fibroblasts suggesting that human inflammatory fibroblasts have a greater potential to drive epithelial expansion. These data shed light on the functional role of inflammatory fibroblasts, further refining our understanding of fibroblast heterogeneity in IPF.
Metastatic Medullary Thyroid Cancer With a Miliary Pattern of Pulmonary Amyloidosis
Deleveaux, S., Khoór, András , Baig, Hassan , Baig, Hassan Z

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4933-A4933

10.1164/ajrccm.2025.211.abstracts.a4933 Get It

Abstract Introduction Medullary thyroid cancer (MTC) is an uncommon malignancy arising from the C-cells of the thyroid gland. It makes up 2% of all thyroid cancers, with both familial and sporadic patterns noted. It is most commonly diagnosed in the fourth to sixth decade of life, with the lungs being a common site of metastasis. We present a case of metastatic MTC with a rare pulmonary presentation. Case Description The patient presented at the age of 28 after having a chronic complaint of stomach pain and diarrhea. Imaging of the abdomen revealed small nodules in the lower pulmonary fields. Dedicated imaging of the chest was subsequently ordered. This study was notable for an enlarged left lobe of the thyroid extending into the mediastinum with two large mediastinal lymph nodes. A fine-needle aspiration of the left neck lymph node was consistent with MTC and there were hematologic findings of elevated calcitonin and CEA. Testing for the RET proto-oncogene was negative. Pathology on total thyroidectomy confirmed the diagnosis, with further sampling identifying metastasis in the thoracic spine (T12). Initial therapy with pazopanib was commenced. After some time on stable therapy, the patient was noted to have waxing and waning pulmonary micro-nodularity associated with increase in his calcitonin levels. There was a finding of a miliary pattern of disease on chest imaging. The pulmonary service was consulted due to these findings in conjunction with sub-acute cough. Pulmonary biopsy was performed, with findings of nodular amyloidosis; Congo red stain highlighted amyloid deposition. Immunohistochemical studies were performed, revealing rare cell groups that were positive for calcitonin, CEA, CAM5.2, TTF-1, chromogranin, and synaptophysin. After further discussion with the Pathology service, the patient was given formal diagnosis of amyloid deposition of the Acal subtype due to metastatic medullary thyroid cancer. Discussion This case highlights a patient diagnosed with sporadic MTC, later found to have metastatic related pulmonary amyloid deposition. While local amyloid deposition can be seen in MTC, it is unusual to have diffuse parenchymal disease due todiffuse parenchymal disease due to distant deposition. There are only four other instances in the literature of a similar presentation. Amyloid deposition is associated with worse outcomes, but the patient had a good outcome with treatment by a tyrosine-kinase inhibitor.
A Rare Presentation of a Rare Disease: Invasive Mucinous Adenocarcinoma Presenting as Multiple Cavitary Nodules
Poleksic, Mia, Egan, A. , Egan, A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4886-A4886

10.1164/ajrccm.2025.211.abstracts.a4886 Get It

Abstract Introduction: Lung cancer is the most frequently diagnosed cancer and leading cause of cancer death worldwide. While adenocarcinoma is the most common subtype of lung cancer, invasive mucinous adenocarcinoma (IMA) only represents an estimated 2-5% of lung adenocarcinomas. IMA has an incidence of just 0.2% among primary lung cancer patients. This rare form of lung cancer provides a significant diagnostic challenge due to its varied clinical and radiological manifestations, often exhibiting features overlapping with pneumonia. We present a case of IMA with radiographic findings of numerous cavitary nodules, an uncommon morphology reported in 3.5% of cases of IMA, originally thought to represent atypical multifocal pneumonia. Description of Case: A 76-year-old man with a history of coronary artery disease status post percutaneous coronary intervention on dual antiplatelet therapy; hypertension; chronic kidney disease; and 40 pack-year smoking history presented to primary care with 6 weeks of worsening cough productive of clear sputum and shortness of breath. He denied a history of fevers, night sweats, unintentional weight loss, recent travel, or sick contacts. A chest x-ray revealed extensive nodular parenchymal opacities in the lower lobes bilaterally concerning for multifocal pneumonia. Subsequent CT chest showed numerous bilateral, poorly-defined nodules with irregular margins and cavitary lesions. He was admitted for acute hypoxic respiratory failure in the setting of presumed atypical multifocal pneumonia. He completed a course of vancomycin and piperacillin/tazobactam. Notably, bronchoscopy with bronchoalveolar lavage and cytology were negative for infection and malignancy, respectively. Additional noninvasive infectious and inflammatory workup was negative and he was ultimately discharged. He was then readmitted to the ICU for respiratory failure where he eventually underwent transbronchial biopsy. Tissue biopsy revealed moderately-differentiated adenocarcinoma with mucinous features. PD-L1 staining was 0%. Genetic testing revealed two separate TP53 mutations, a KRAS G12D mutation, and SMAD4 alteration. Chemotherapy with carboplatin and pemetrexed was initiated inpatient. He had objective and subjective improvement and was ultimately discharged to continue treatment in the outpatient setting. Discussion: This case represents an uncommon presentation of an already rare form of lung cancer underscoring the diagnostic difficulty in the setting of overlapping clinical and radiological manifestations. Clinicians must consider malignancy when a patient with presumed pneumonia is not improving despite antibiotics. Bronchoscopy with both BAL and transbronchial biopsy is often required to make the diagnosis and exclude other etiologies. Early consideration of alternative diagnoses can improve patient outcomes and help avoid progressive respiratory failure.
Tracheal Chondrosarcoma Presenting as Variable Extrathoracic Airway Obstruction Surgically Resected on Veno-venous Extracorporeal Membrane Oxygenation
Mangin, W.W., Thomas, C, Mangin, W W, Thomas, C.F.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4861-A4861

10.1164/ajrccm.2025.211.abstracts.a4861 Get It

Abstract Tracheal tumors are uncommon, comprising only 0.2% of respiratory tract malignancies, with the majority of these being squamous cell carcinoma and adenoid cystic carcinoma. Tracheal chondrosarcomas are a rare cause, with only thirty-four cases described in literature between 1959 and 2020. Although often asymptomatic, nonspecific symptoms including dyspnea, nonproductive cough, and wheezing contribute towards misdiagnosis with diseases such as asthma or chronic obstructive pulmonary disease (COPD). Delay in diagnosis can potentially lead to complete tracheal obstruction and airway compromise. Treatment of choice is surgical resection, with overall 10-year survival to be around 95%. Although recurrence rates are minimal when treated with open surgical resection with negative margins, post-surgical surveillance is recommended. Use of extracorporeal membrane oxygenation (ECMO) during surgery offers an alternative to endotracheal intubation, potentially making complete tumor resection easier. A 56-year-old male never smoker with past medical history of hereditary hemochromatosis, requiring phlebotomy, severe obstructive sleep apnea status post right upper airway nerve stimulator placement, and a history of left vocal cord granuloma that presented to an outpatient pulmonology clinic for chronic cough and exertional dyspnea. Initially, the patient was started on a proton pump inhibitor and nasal corticosteroid, without improvement in symptoms. He subsequently underwent pulmonary function testing, which showed flow volume loop suspicious for variable extrathoracic airway obstruction. Chest computed tomography (CT) scan was significant for a 2.2 cm soft tissue lesion in the left upper mediastinum with protrusion through the tracheal wall. PET scan did not show significant FDG avidity. A 1.5 centimeters lesion situated about 5 centimeters above the carina was found on rigid bronchoscopy and biopsies were negative for malignancy. Patient subsequently underwent video-assisted thoracoscopic surgery (VATS) robotic-assisted tracheal resection on Veno-venous ECMO. Final pathology was consistent with G1 chondrosarcoma, with negative margins. On follow up, patient's respiratory symptoms have resolved and periodic surveillance with repeat chest CTs is planned. This unique case offers an important reminder of a potential cause of upper airway obstruction, not only highlighting the potential of pulmonary function testing to aid in early detection, but also the successful use of ECMO in surgical resection.
A Rare Presentation of Pulmonary Kaposi Sarcoma
Sahota, Raguwinder , Sahota, R.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4860-A4860

10.1164/ajrccm.2025.211.abstracts.a4860 Get It

Abstract Introduction Pulmonary Kaposi Sarcoma (KS) is a rare manifestation of human immunodeficiency virus (HIV) infection, predominantly seen in immunocompromised patients and infrequently in the era of antiretroviral therapy (ART). KS is a mesenchymal neoplasm arising from blood and lymphatic vessel endothelial cells, primarily affecting homosexual or bisexual men with HIV. Diagnosis typically relies on a combination of clinical evaluation, radiographic imaging, and histopathological confirmation via biopsy. This case underscores the importance of considering pulmonary KS in the differential diagnosis of acute respiratory failure in patients with advanced HIV, even with ART. Case presentation A 44-year-old male with newly diagnosed HIV/AIDS was admitted to the ICU for acute hypoxic respiratory distress. He had initially presented months prior with skin rashes, an HIV viral load of 1040, and a CD4 count of 148, at which time antiretroviral therapy (Biktarvy) was initiated. A chest CT scan revealed diffuse bronchial wall thickening, ground-glass opacities, interlobular septal thickening in a perihilar and upper lung predominant distribution, and bilateral pleural effusions. Pleural fluid analysis confirmed an exudative profile, with worsening hemorrhagic effusions suggestive of visceral Kaposi sarcoma. Bronchoscopy indicated submucosal changes, especially in the left upper lobe and proximal main stems. Skin biopsy, fine-needle aspiration of an axillary lymph node, and a left upper lobe lung biopsy confirmed Kaposi sarcoma. The biopsy showed elevated EBV-positive cells, HHV8-positive sarcoma cells, CMV-negative status, and mixed T and B cells (CD3 and CD20). Lung immunohistochemistry indicated neoplastic cells positive for FLI1, CD31, and patchy HHV8 staining, but negative for AE1/AE3. With a diagnosis of Kaposi sarcoma involving pleuropulmonary, cutaneous, visceral, and lymph node regions, the patient was started on systemic chemotherapy with doxorubicin. Unfortunately, KS had spread signficantly and patient was made comfort care as he was having respiratory failure despite on mechanical ventilator. Discussion Before the advent of antiretroviral therapy (ART), Kaposi's sarcoma carried a poor prognosis, with pulmonary KS survival averaging 2-10 months. ART alone is generally sufficient for asymptomatic patients, often leading to lesion regression and forming the foundation of HIV-associated KS management. For symptomatic or progressive cases, systemic chemotherapy—typically pegylated liposomal doxorubicin—is recommended, as anthracyclines offer effective, lower-toxicity treatment. Paclitaxel may be used in patients unresponsive to anthracyclines. Although less common for KS, localized radiation therapy can provide symptomatic relief in cases of airway obstruction, hemoptysis, or pleuritic chest pain.
The Impact of Frailty and Sarcopenia in Lung Cancer Patients
Bellar, Annette , Zein, Joe , Welch, Nicole , Dasarathy, S., Attaway, Amy

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4811-A4811

10.1164/ajrccm.2025.211.abstracts.a4811 Get It

Abstract Background. Sarcopenia (i.e. skeletal muscle loss) and physical frailty are significant contributors to adverse clinical outcomes in lung cancer patients. Nutritional intake and physical activity influence skeletal muscle mass and strength. We determined the impact of lung cancer on clinical outcomes in hospitalized patients with sarcopenia, frailty, or sarcopenia+frailty. Design. The Nationwide Inpatient Sample (NIS) (years 2018-2020) from the United States was analyzed to study adult hospitalized patients with a diagnosis of lung cancer. Sarcopenia and frailty were defined by ICD10 codes that have been previously validated. Multivariate regression models were generated to determine the clinical impact of sarcopenia, frailty, or sarcopenia+frailty in patients with a diagnosis of lung cancer as compared to a general medical population (GMP) without lung cancer. Age was restricted to >40 years old for both cohorts because lung cancer is rare in those less than 40 years old. Models were adjusted for age, race, sex, and comorbidities (cardiovascular disease, anemia, coagulopathy, HIV, depression, diabetes mellitus, and COPD). Results. Compared to the GMP (n=126,099), patients with lung cancer (n=241,913) were older (mean+SD age: 69.6+10.0 vs. 67.6+13.3 years, p<0.001), and had a higher prevalence of sarcopenia (22.5% vs 9.0%, p<0.001), frailty (53.4% versus 49.8%, p<0.001), and sarcopenia+frailty (15.3% versus 6.8%, p<0.001). COPD was common and found in 52.3% of lung cancer patients and 20.2% of the GMP. In lung cancer patients, the most common medical reasons for admission were sepsis, pneumonia, and COPD exacerbation. In GMP patients, the most common medical reasons for admission were sepsis, congestive heart failure, and acute kidney injury. In lung cancer patients, frailty had the greatest association with mortality (unadj OR 3.12, 95% CI: 3.02-3.23; adj OR 3.04, 95% CI: 2.91-3.17). Sarcopenia+frailty was most associated with greater healthcare utilization including greater healthcare cost (unadj OR 1.31, 95% CI: 1.29-1.32; adj OR 1.28, 95% CI: 1.26-1.30) and length of stay (unadj OR 1.57, 95% CI: 1.55-1.58; adj OR 1.50, 95% CI: 1.48-1.52). Sarcopenia+frailty were more likely to require additional healthcare facilities upon discharge and were the least likely to be discharged to home (unadj OR 0.32, 95% CI: 0.32-0.33; adj OR 0.35, 95% CI: 0.33-0.36). (see Table 1). Conclusion. While frailty was most associated with in-hospital mortality in lung cancer patients, sarcopenia+frailty was most associated with greater healthcare utilization. Our findings highlight the need to develop targeted interventions to improve clinical outcomes in lung cancer patients with sarcopenia and/or frailty.
Functional Genomic Modules in Idiopathic Pulmonary Fibrosis Mesenchymal Progenitor Cells Identified by Weighted Gene Co-expression Network Analysis
Yang, Libang , Xia, H., Kubbara, Aahd , Henke, Craig A. , Jbeli, A. , Xia, H., Kim, Hyun Joo , Bitterman, Peter B.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4699-A4699

10.1164/ajrccm.2025.211.abstracts.a4699 Get It

Abstract RATIONALE: Mesenchymal progenitor cells (MPCs) in the lungs of individuals with Idiopathic Pulmonary Fibrosis (IPF) show intrinsic fibrogenic properties, possessing a distinct transcriptomic profile and maintaining fibrogenic activity, which contributes to the fibroblast population in IPF. We hypothesize that IPF MPCs are distinguished from control MPCs by a unique gene interaction network. METHODS: We analyzed bulk RNA-seq data, available on the Gene Expression Omnibus (GEO) under accession numbers GSE97038 and GSE276568. In these experiments, CD44hi MPCs were isolated through flow cytometry from mesenchymal cell lines derived from IPF patients (explanted lungs from live IPF patients after lung transplant) and control subjects (lobectomy for clinical reasons) using antibodies against CD44 and SSEA4. The pooled dataset comprises nine IPF and nine control MPC lines. We identified differentially expressed genes (DEGs) in IPF MPCs compared to controls using DESeq and performed pathway enrichment analysis on DEGs using Gene Ontology (GO). We also conducted Gene Set Enrichment Analysis (GSEA) with gene sets related to stemness, pluripotency, and self-renewal. Weighted gene co-expression network analysis (WGCNA) identified functional modules specifically associated with IPF MPCs. RESULTS: Applying an adjusted p-value threshold of 0.05, we identified 134 DEGs in IPF MPCs compared to controls. GO analysis showed significant enrichment in pathways associated with leukocyte migration, extracellular matrix organization, and cell differentiation and growth. GSEA highlighted significant enrichment in two gene sets related to stemness, with adjusted p-values of 0.002 and 0.048. Using WGCNA, we identified 16 functional modules, one of which reached significance based on an adjusted p-value threshold of 0.05 and a correlation coefficient cutoff of 0.45. This significant module demonstrated a positive correlation with IPF status (correlation coefficient of 0.69, adjusted p-value 0.0085). CONCLUSION: This study is the first to characterize a distinct gene expression profile in IPF MPCs compared to controls, highlighting enriched biological processes relevant to IPF pathogenesis. GSEA results further support the hypothesis that IPF MPCs display stem cell-like gene expression patterns, including genes associated with pluripotency and self-renewal. Additionally, we identified functional gene modules that significantly correlate with the fibrogenic properties of IPF MPCs, including hub genes that may play critical roles in promoting fibrosis in IPF. These findings deepen our understanding of IPF MPC biology and identify potential targets for future research. We plan to expand this approach by increasing the sample size to enhance statistical power, aiming to identify more robust functional modules and their highly connected hub genes.
Lung Endothelial MiR-205-5P Induces a Pro-fibrotic Endothelial Secretory State and Promotes Lung Fibroblast Activation
Roos, B., Elliot, S., Csete, M.K. Glassberg, Tschumperlin, Daniel J. , Ligresti, Giovanni , Muscato, Giuseppe , Sciacca, ‬‬‬‬‬‬Eva , Raslan, Ahmed , Vancheri, Carlo , Elliot, Sharon J. , Caporarello, Nunzia

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4627-A4627

10.1164/ajrccm.2025.211.abstracts.a4627 Get It

Abstract RATIONALE: Vascular dysfunction contributes to pathological tissue remodeling in aging-associated disease such as Idiopathic Pulmonary Fibrosis (IPF). IPF is an incurable lung disease characterized by progressive accumulation of scar-forming fibroblasts and several vascular alterations, including endothelial transcriptional changes leading to a pro-fibrotic endothelial secretory phenotype. To date, the mechanisms governing these transcriptional changes remain largely unexplored. To fill this gap, we sought to investigate whether microRNAs (miRNAs), small non-coding RNA that function as key gene expression regulators, modulate the transcriptional changes of the endothelium associated with progressive pulmonary fibrosis. METHODS AND RESULTS: miRNA expression profiling of lung ECs (LECs) sorted from aged mice with persistent lung fibrosis revealed upregulation of miR-205-5p. Further analysis demonstrated that endothelial miR-205-5p was strongly upregulated in an additional mouse model of progressive lung fibrosis induced by repetitive bleomycin dose as well as in human LECs purified from IPF lungs. RNA-seq analysis of normal human LECs overexpressing miR-205-5p revealed reduction of genes associated to endothelial identity (e.g. PECAM1, ERG, NOS3), and an increase of genes encoding for soluble pro-inflammatory and pro-fibrotic molecules, including TGFBI, TGFB2, TGFB3, CXCL10, CCL5, IL1B and FAS compared to normal LECs transfected with a control mimic. Consistently, conditioned medium from miR-205-5p overxpressing LECs exerted a pro-fibrotic activity on quiescent human lung fibroblasts, as demonstrated by upregulation of a panel of profibrotic transcripts (e.g. COL1A1, CTHRC1, FN1 and TNC) and elevated Collagen I deposition compared to human lung fibroblasts exposed to conditioned medium generated by human LECs transfected with a control mimic. CONCLUSION: Altogether, our findings suggest that lung endothelail miR-205-5p induces loss of endothelial cell identity and drives the secretion of pro-fibrotic molecules that promote the transition of quiescent fibroblasts into scar-forming fibroblast through paracrine signal. Our data set the stage for further investigations into the role of miR-205-5p and associated pathways in lung vascular injury responses, with the long term goal of targeting endothelial dysfunction for slowing the progression of pulmonary fibrosis.
Through the Window: Addressing Complex Empyema in a Transplant Patient
Hu, A.W., Pennington, Kelly M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4587-A4587

10.1164/ajrccm.2025.211.abstracts.a4587 Get It

Abstract Lung transplant recipients are at high risk for pleural complications following transplantation. Pleural effusions are nearly universal immediately after transplant, but most resolve spontaneously in the following weeks. For persistent effusions, there is no consensus on the optimal management strategy, and risks of potential procedures must be balanced with long-term complications. A 58-year-old male presented with 3 months of severe fatigue, brain fog, chills without fever, poor appetite, and weight loss. His medical history included bilateral redo lung transplant 7 months prior for chronic lung allograft dysfunction, type II diabetes mellitus, chronic kidney disease stage IIIb, and heart failure with preserved ejection fraction. His immunosuppression regimen included tacrolimus, prednisone, and mycophenolate, with prophylaxis of trimethoprim/sulfamethoxazole and posaconazole. At the follow up visit, spirometry revealed a significant decline in lung function (FVC 2.31 to 1.97; FEV1 1.84 to 1.51). He was admitted for urgent evaluation. A CT scan revealed a large (20 cm) multiseptated left-sided empyema or hematoma causing mass effect on the spleen and distal pancreas. A 12 French locking loop pigtail catheter was placed into the left pleural space, and fluid analysis showed a total nucleated cell count of 23,306/mcL (100% neutrophils), LDH >9000 U/L, total protein of 1.3 g/dL, glucose <2 mg/dL, and pH <6.80, consistent with empyema. Fungal cultures identified Scedosporium species. The patient received six doses of intrapleural lytics, yielding 3.3 liters of serosanguinous drainage. However, repeat CT showed residual thick fibrinous peel surrounding the pleura. Video-assisted thoracoscopic decortication revealed extensive pleural infection with minimal healthy mucosa, allowing only limited decortication due to bleeding risk. He then underwent open-window thoracostomy (Clagett window) for ongoing drainage, followed by three additional debridement procedures and antifungal therapy with liposomal amphotericin B and voriconazole. This case illustrates the insidious onset of empyema in immunocompromised hosts, such as lung transplant patients, and highlights the rare need for open-window thoracostomy in severe pleural infections.